eMolecules
eMolecules operates a chemical search-and-fulfillment platform for pharmaceutical and biotech drug discovery, aggregating 83+ million SKUs from 300+ suppliers across 35 countries. It serves 14 of the top 15 global pharmaceutical companies and nearly 1,000 total customers with compound procurement, management, virtual screening, and automated synthesis services.
- Company typePrivate
- Founded2005
- HeadquartersSolana Beach, United States
- Headcount11–50
- GTM typeB2B
- OfferingDigital Commerce or Content
What eMolecules does
eMolecules, Inc. operates a chemical search-and-fulfillment platform serving pharmaceutical, biotechnology, academic, and agricultural chemistry researchers. Founded in 2005 in San Diego, the company aggregates a catalog of 83+ million specialty chemistry and biology SKUs from over 300 suppliers across 35 countries, making it the largest readily available chemical inventory accessible through a single digital interface. The platform supports structure-based, substructure, exact, and similarity searches via a proprietary chemical search engine, with a self-serve ecommerce portal at search.emolecules.com and enterprise field sales teams serving 14 of the top 15 global pharmaceutical companies.
The company's product portfolio spans building blocks (9M+ SKUs), screening compounds (24.6M+ SKUs), and biological reagents (6M+ SKUs), supplemented by a virtual chemical space (eXplore) of 8.3+ trillion synthesizable compounds that, following the 2024 Synple Chem AG acquisition, was unified with Synple Space into a 67+ trillion compound virtual library accessible via BioSolveIT's infiniSee platform. The 2024 acquisition also added the Synple2 automated synthesizer, a hardware platform enabling synthesis-on-demand via encapsulated reagent cartridges. Service revenue is generated through compound management, reformatting, storage, and custom chemistry offerings operated from facilities in San Diego, Newark (DE), Cumberland (MD), Stevenage (UK), Zoetermeer (Netherlands), and Kemptthal (Switzerland).
The business model combines transaction-based markups on compound sales, multi-year contracts for compound management services, and recurring subscription access to virtual chemical spaces. Backed by Avista Capital Partners since March 2022, eMolecules has executed a roll-up strategy completing four acquisitions (Frontier Scientific, Frontier Agricultural Sciences, Specs Compound Handling, Synple Chem) between 2022 and 2024, growing to approximately 140 employees across seven global entities. The company sells through enterprise field sales for major pharma, regional inside sales for mid-market and SMB, and a self-serve ecommerce platform, with ongoing geographic expansion into Japan and South Korea and product line diversification into battery chemicals and high-volume essentials.
eMolecules firmographics
Firmographics- Name
- eMolecules
- Legal name
- eMolecules, Inc.
- Website
- https://emolecules.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- eMolecules operates a chemical search-and-fulfillment platform for pharmaceutical and biotech drug discovery, aggregating 83+ million SKUs from 300+ suppliers across 35 countries. It serves 14 of the top 15 global pharmaceutical companies and nearly 1,000 total customers with compound procurement, management, virtual screening, and automated synthesis services.
- Ownership category
- akta.pro rank
eMolecules industry classification
Industry- Product category
- Drug Discovery Chemical Marketplace
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE)
Keywords
Where eMolecules is headquartered
LocationHeadquarters
- HQ city
- Solana Beach
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
eMolecules business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Chemical Compound Sales: Transaction-based sales of building blocks, screening compounds, and other chemical reagents through the e-commerce platform. Revenue derived from mark-up on compounds sourced from supplier network.
- Compound Management Services: Services including compound reformatting, storage, quality control, and management services for pharmaceutical and biotech customers.
- Custom Chemistry Services: Custom synthesis and chemistry services including automated synthesis platform and reaction kits.
- Virtual Compound Access: Access to eXplore virtual chemical space (8.3+ trillion compounds) and Synple virtual library (67 trillion+ compounds) for virtual screening and synthesis-on-demand.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Building Blocks and Screening Compounds |
| Other | Multi-year contract | Compound Management Services |
| Subscription | Annual | Virtual Library Access |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
eMolecules product offering
Product offeringCore offering
eMolecules operates a chemical search-and-fulfillment platform that aggregates over 83 million specialty chemistry and biology SKUs from 300+ suppliers across 35 countries, enabling pharmaceutical and biotech researchers to search, find, and procure building blocks, screening compounds, and biological reagents. The platform combines proprietary structure-search technology, tiered supplier delivery, an 8.3+ trillion compound virtual chemical space (eXplore), automated synthesis systems (Synple2), and integrated compound management services including reformatting, storage, and quality control.
Product overview
eMolecules operates as a chemical search-and-fulfillment platform providing integrated ecommerce software and services for pharmaceutical, biotechnology, and academic drug discovery research. The platform combines a core product portfolio (Building Blocks with 9M+ compounds, Screening Compounds with 24.6M+ compounds, and Biological Reagents with 6M+ items) with a virtual chemical space (eXplore spanning 8.3+ trillion synthesizable compounds) and automated synthesis solutions (Synple2 synthesizer). The service layer includes compound management, reformatting, storage, quality control, and custom synthesis services, all powered by a chemical search engine with structure-based, similarity, and target-based search capabilities. Recent acquisitions (Frontier Scientific, Specs Compound Handling, Synple Chem) expanded the company into compound management, storage facilities, and automated synthesis services.
Differentiator
Problem solved
Functional benefit
Brands
- eXplore: The world's largest commercially available virtual chemical space containing over 8.3 trillion synthesizable compounds, created in collaboration with BioSolveIT.
- Synple Space
- eMolecules Essentials
- Battery Chemicals
- Synple2
Products and services
- Building Blocks Search and order from over 9 million building block compounds from a global network of trusted suppliers with Tier 1 (1-5 day) and Tier 2 (2-10 day) delivery options for pharmaceutical and biotech drug discovery researchers.
- Screening Compounds Search and order from over 24.6 million screening compounds for high-throughput drug discovery screening programs serving pharmaceutical and biotech researchers.
- Biological Reagents Search and order from over 6 million biological reagents including antibodies with detailed target, clonality, host species, and application data for life sciences research.
- eXplore Virtual Chemical Space World's largest commercially available virtual chemical space with 8.3+ trillion synthesizable compounds built from readily available building blocks using 45 proven reactions, accessible via BioSolveIT infiniSee and providing an average compound cost of approximately $150 or less with 94%+ synthesis success rate.
- eMolecules Essentials High-volume everyday research chemicals product line designed to streamline sourcing, reduce supplier complexity, and optimize chemical spend without compromising quality.
- Battery Chemicals Specialized battery chemical compounds providing streamlined access to essential compounds driving battery innovation and research for energy storage applications.
- Synple2 Automated Synthesizer Automated chemistry synthesis system enabling chemists to execute complex synthetic processes with a single button press using encapsulated reagent cartridges, providing synthesis-on-demand capabilities for small molecule drug discovery.
- Compound Management Services Full-service compound management including storage, reformatting, and distribution services for pharmaceutical and biotech screening programs, with facilities in the US (Newark, Cumberland) and Europe (Zoetermeer).
- Reformatting Services Screening compound reformatting services converting compounds between different plate formats and concentrations for high-throughput screening applications.
- Storage Services Temperature-controlled compound storage facilities for managing and maintaining chemical compound inventories for pharmaceutical and biotech customers.
- Quality Control Services Analytical and quality control services ensuring compound identity, purity, and integrity for research and screening compound inventories.
- Custom Chemistry Services Custom synthesis services for specialty chemical compounds not available in standard catalogs, serving pharmaceutical, biotechnology, industrial chemical, government, and academic sectors.
- Automated Synthesis Platform Service Synthesis-on-demand services using automated chemistry platforms (Synple) for efficient small molecule synthesis serving drug discovery customers.
- Personalized Websites Custom e-commerce websites tailored to specific customer procurement needs with integrated compound search and ordering functionality.
Quantifiable outcome
- Near-100% reliable on-time delivery
- +3 more outcomes
Companies that use eMolecules
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
eMolecules technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature5 records
eMolecules partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- PharmaceleracorePartnership announced October 13, 2025 to launch an integrated drug discovery solution combining Pharmacelera's ExaScreen® with eMolecules' eXplore/Synple library. The solution streamlines the process from virtual screening to testing new compounds, accelerating early-stage drug development.
- BioSolveITcorePartnership for eXplore virtual chemical space creation and distribution. Synple Space made available across all BioSolveIT platforms and tools. Access via infiniSee chemical space navigation platform.
- AlipheroncoreStrategic collaboration integrating real-time data from eMolecules' eXplore-Synple virtual space to Alipheron software. Also announced integration of Alipheron's Pharos-3D search technology with the 67 trillion compound Synple-eXplore virtual chemical space in May 2026.
- Kishida ChemicalcorePartnership with Kishida Chemical, a highly respected leader in the Japanese chemical supply industry, expanding eMolecules' presence and distribution in Japan.
- HITS.aiminorStrategic collaboration formalized through Memorandum of Understanding signed at HITS.ai headquarters in South Korea for AI-driven drug discovery initiatives.
- Knight-Chemicals (Phil Baran)minorNew supplier partnership bringing innovative new compounds by Phil Baran to eMolecules' catalog.
- OpticcorePartnership to accelerate AI-powered drug discovery by providing seamless access to eMolecules' chemical library via Optic's BIOPTIC AI platform. Researchers can identify compounds from commercial catalogs using target names or known ligands.
- Synple Chem AGcoreAcquisition of Synple Chem AG strengthens eMolecules' position as global one-stop-shop solution provider. Synple specializes in automated chemical synthesis systems and provides access to 7+ trillion virtual compounds. Combined with eXplore creates 67+ trillion compound virtual library.
- Specs Compound Handling B.V.coreAcquisition of Specs Compound Handling B.V. expands eMolecules' compound management capabilities, particularly in Europe. Specs provides chemical compound management services to pharmaceutical, biotechnology and academic sectors with facilities in Netherlands and Maryland, USA.
- Frontier Scientific Inc. and Frontier Agricultural Sciences Inc.coreAcquisition of Frontier Scientific Inc. and Frontier Agricultural Sciences Inc. established one-stop shop for chemical compound procurement and management. FSI provides chemical materials management and custom research services; FAS serves entomology research community.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
eMolecules competitors and assessment
Company assessmentDirect peers
- ChemSpace: ChemSpace operates an online chemical marketplace aggregating building blocks, screening compounds, and custom synthesis services for drug discovery researchers. It is a direct digital competitor to eMolecules' e-commerce and search platform with overlapping customer base.
- Enamine: Enamine is a leading European supplier of building blocks, screening compounds, and custom chemistry services, with a similarly large catalog and direct relationships with pharmaceutical discovery teams. It is a direct competitor in compound sourcing and custom synthesis with comparable target customers.
- MolPort: MolPort is a chemical sourcing marketplace that aggregates compounds from multiple suppliers for pharmaceutical and academic researchers. It is a direct peer in the multi-supplier chemical procurement model with comparable search and order platform functionality.
- Combi-Blocks: Combi-Blocks is a San Diego-based supplier of building blocks and screening compounds serving pharmaceutical, biotech, and academic drug discovery researchers. It is a direct competitor in the building blocks and screening compound supply market with similar customer profiles.
- Specs (now part of eMolecules): Specs was historically a direct peer offering screening compound libraries and compound management services before being acquired by eMolecules in 2023. It remains relevant as a benchmark for the compound management services segment eMolecules now competes in directly.
Emerging players
- BioSolveIT: BioSolveIT provides chemical space navigation software (infiniSee) and virtual screening tools that integrate with eMolecules' eXplore library. It is a technology partner but also operates in adjacent cheminformatics software space where competitive overlap could grow.
- Pharmacelera: Pharmacelera develops computational chemistry and virtual screening software (ExaScreen) and has a formal partnership with eMolecules. It represents an emerging player at the intersection of AI drug discovery and chemical library access where strategic competition or partnership dynamics could shift.
Broad incumbents
- Thermo Fisher Scientific: Thermo Fisher Scientific offers an extensive portfolio of research chemicals, custom synthesis, and compound management services through its Life Sciences Solutions and Laboratory Products segments. It serves similar pharma/biotech procurement customers at greater scale and with broader instrumentation offerings.
- WuXi AppTec: WuXi AppTec is a global CRO/CDMO offering compound management, custom synthesis, and drug discovery services to pharmaceutical and biotech customers. It is a broad incumbent in discovery chemistry services with significant overlap to eMolecules' compound management and custom synthesis offerings.
- Sigma-Aldrich (MilliporeSigma / Merck KGaA): MilliporeSigma, the life science business of Merck KGaA, is the world's largest supplier of research chemicals, building blocks, and screening compounds. It is a broad incumbent with overlapping catalog breadth, global distribution, and pharma customer base, though it operates across a much wider life sciences portfolio beyond drug discovery procurement.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
eMolecules social profiles
Digital presenceeMolecules compliance and trust
Trust signalCompliance7 records
eMolecules financial estimates
Financial estimateRevenue estimate
Valuation estimate
eMolecules leadership team
Management profileNumber of profiles
Profiles3 records
eMolecules subsidiaries and ownership
Company hierarchySubsidiaries4 records
eMolecules funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
eMolecules M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about eMolecules
What does eMolecules do?
eMolecules operates a chemical search-and-fulfillment platform that aggregates over 83 million specialty chemistry and biology SKUs from 300+ suppliers across 35 countries, enabling pharmaceutical and biotech researchers to search, find, and procure building blocks, screening compounds, and biological reagents. The platform combines proprietary structure-search technology, tiered supplier delivery, an 8.3+ trillion compound virtual chemical space (eXplore), automated synthesis systems (Synple2), and integrated compound management services including reformatting, storage, and quality control.
Is eMolecules a public or private company?
eMolecules is a private company. It is classified as private equity controlled and is currently operating.
When was eMolecules founded?
eMolecules was founded in 2005. It employs 11 to 50 people.
Where is eMolecules based?
eMolecules is headquartered in Solana Beach, United States, in the North America region.
How does eMolecules make money?
Four revenue lines are on record. Chemical Compound Sales are the primary driver. The others are compound Management Services, custom Chemistry Services and virtual Compound Access.
Who are eMolecules's main competitors?
Direct peers on record are ChemSpace, Enamine, MolPort, Combi-Blocks and Specs (now part of eMolecules). Emerging players are BioSolveIT and Pharmacelera. Broad incumbents are Thermo Fisher Scientific, WuXi AppTec and Sigma-Aldrich (MilliporeSigma / Merck KGaA).
Does eMolecules have an API?
No public API is recorded for eMolecules.
What industry is eMolecules in?
eMolecules's product category is Drug Discovery Chemical Marketplace. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 541714 and its SIC code is 8731.